Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To study the immediate and chronic effects of high-dose, long-term human IV immunoglobulin (hIVIg) therapy in two patients with advanced adult-onset Rasmussen’s encephalitis (RE).
Background: Despite advances in our understanding of the autoimmune pathogenesis of RE, medical options for chronic treatment are limited.
Methods: In an open-label treatment trial, treatment started with monthly cycles of high-dose hIVIg (0.4 g/kg/d for 5 days) followed by maintenance therapy (0.4 g/kg 1 day each month) after the patients’ conditions began to improve. Outcome measures included clinical, psychological, functional, and laboratory assessments before and at relevant intervals throughout 1 year of treatment.
Results: In both patients, unrelenting pretreatment deterioration halted, and after this they displayed striking improvements in seizure control, hemiparesis, and cognition that produced useful recovery of function. Improvements were delayed until after 2 to 4 monthly cycles of high-dose hIVIg and continued when patients switched to maintenance treatment. Their recoveries were accompanied by increased cerebral perfusion on interictal SPECT and suppression of inflammatory markers in CSF.
Conclusions: hIVIg can be a useful, possibly disease-modifying, long-term therapy for adult-onset RE that should be considered before radical surgery is performed. Because improvements can be delayed, we propose guidelines for intensive and prolonged trials of immunomodulatory therapy in adults with this syndrome.
- Received June 3, 1998.
- Accepted in final form November 21, 1998.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Rasmussen encephalitis and comorbid autoimmune diseasesA window into disease mechanism?Dina Amrom, Demet Kinay, Yvonne Hart et al.Neurology, August 20, 2014 -
Articles
Nonconvulsive status epilepticus of frontal originP. Thomas, B. Zifkin, O. Migneco et al.Neurology, April 01, 1999 -
Article
Immunomodulation With Azathioprine Therapy in Rasmussen SyndromeA Multimodal EvaluationSerena Pellegrin, Torsten Baldeweg, Suresh Pujar et al.Neurology, October 12, 2020 -
Brief Communications
Persistence of ictal activity after functional hemispherectomy in Rasmussen syndromePierre Thomas, Benjamin Zifkin, Gabriela Ghetâu et al.Neurology, January 14, 2003